Register for our free email digests:
Latest From HanAll Pharmaceutical Co. Ltd.
Dr. Benjamin R Cowen, COO of ImmunoMet Therapeutics, reveals how the Houston-based startup is developing OXPHOS inhibitors to treat drug resistant and relapse cancers.
Hanmi's surprising success in R&D this year has left people wondering what strategy the leading South Korean pharma firm may take next to transform into a big global player like Takeda. With an expected massive inflow of cash from a series of big licensing out deals with multinationals, it may be poised to change its R&D strategy and even engage in some M&A.
Yuhan has been seen as one of the less aggressive South Korean pharma firms in terms of beefing up R&D. But now, the company may be shifting its strategy as it has decided to become the second biggest shareholder of local bioventure Bioneer, in a move to strengthen its pipeline including immuno-oncology drugs and to diversify into new businesses.
The planned acquisition of South Korea’s HanAll Biopharma by its bigger rival Daewoong Pharmaceutical has met a setback as unionized workers are HanAll protesting the plan, demanding compensation and job security amid concerns over the transaction.
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Elekta AB
- Senior Management
Richard Hausmann, PhD, Pres. & CEO
Hakan Bergstrom, CFO
Ian Alexander, Chief Commercial Officer
John Lapre, EVP, Research & Innovation
Maurits Wolleswinkel, EVP, Mktg. & Strategy
- Contact Info
Phone: (46) 8 587 254 00
P.O. Box 7593 Stockholm, SE-103 93
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.